Stock 0O59 SANOFI
Add to a list
To use this feature you must be a member
Log inSign up

Ratings Sanofi CINNOBER BOAT

Equities

0O59

FR0000120578

Real-time Estimate Tradegate
Other stock markets
 10:03:50 2024-06-28 am EDT 		5-day change 1st Jan Change
89.86 EUR 0.00% Intraday chart for Sanofi 0.00% 0.00%
Jun. 27 CAC40: caution prevails ahead of crucial deadlines CF
Jun. 27 CAC40: consolidates solo, OAT/Bund spread widens to 81Pb CF

Summary

  • The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.

Strengths

  • The company's EBITDA/Sales ratio is relatively high and results in high margins before depreciation, amortization and taxes.
  • The company returns high margins, thereby supporting business profitability.
  • The company is in a robust financial situation considering its net cash and margin position.
  • Analysts covering this company mostly recommend stock overweighting or purchase.
  • Analyst opinion has improved significantly over the past four months.
  • Consensus analysts have strongly revised their opinion of the company over the past 12 months.

Weaknesses

  • For the last 12 months, analysts have been regularly downgrading their EPS expectations. Analysts predict worse results for the company against their predictions a year ago.

Ratings chart - Surperformance

Sector: Pharmaceuticals

1st Jan change Capi. Investor Rating ESG Refinitiv
SANOFI Stock Sanofi
0.00% 120B -
ELI LILLY AND COMPANY Stock Eli Lilly and Company
+56.12% 819B
C+
JOHNSON & JOHNSON Stock Johnson & Johnson
-6.79% 351B
C+
MERCK & CO., INC. Stock Merck & Co., Inc.
+18.86% 329B
B-
ABBVIE INC. Stock AbbVie Inc.
+9.34% 298B
C+
ASTRAZENECA PLC Stock AstraZeneca PLC
+17.02% 242B
B+
ROCHE HOLDING AG Stock Roche Holding AG
+2.21% 225B
A+
NOVARTIS AG Stock Novartis AG
+13.31% 217B
B-
AMGEN INC. Stock Amgen Inc.
+8.64% 168B
C+
PFIZER, INC. Stock Pfizer, Inc.
-3.33% 158B
C+
Investor Rating
Trading Rating
ESG Refinitiv
-

Financials

Sales growth
Earnings Growth
EBITDA / Sales
Profitability
Finances

Valuation

P/E ratio
EV / Sales
Price to Book
Price to Free Cash Flow
Yield

Momentum

1 year Revenue revision
4 months Revenue revision
7 days Revenue revision
1 year EPS revision
4 months EPS revision

Consensus

Analyst Opinion
Potential Price Target
4m Target Price Revision
4m Revision of opinion
12m Revision of opinion

Business Predictability

Analyst Coverage
Divergence of Estimates
Divergence of analysts' opinions
Divergence of Target Price
Earnings quality

Technical analysis

ST Timing
MT Timing
LT Timing
RSI
Bollinger Spread
Unusual volumes
  1. Stock Market
  2. Equities
  3. SAN Stock
  4. 0O59 Stock
  5. Ratings Sanofi